237 related articles for article (PubMed ID: 30186836)
21. Gene Therapy.
Thorne B; Takeya R; Vitelli F; Swanson X
Adv Biochem Eng Biotechnol; 2018; 165():351-399. PubMed ID: 28289769
[TBL] [Abstract][Full Text] [Related]
22. A new large-scale manufacturing platform for complex biopharmaceuticals.
Vogel JH; Nguyen H; Giovannini R; Ignowski J; Garger S; Salgotra A; Tom J
Biotechnol Bioeng; 2012 Dec; 109(12):3049-58. PubMed ID: 22688835
[TBL] [Abstract][Full Text] [Related]
23. Manufacturing human mesenchymal stem cells at clinical scale: process and regulatory challenges.
Jossen V; van den Bos C; Eibl R; Eibl D
Appl Microbiol Biotechnol; 2018 May; 102(9):3981-3994. PubMed ID: 29564526
[TBL] [Abstract][Full Text] [Related]
24. Engineering T Cell Development for the Next Generation of Stem Cell-Derived Immunotherapies.
Michaels YS; Durland LJ; Zandstra PW
GEN Biotechnol; 2023 Apr; 2(2):106-119. PubMed ID: 37928777
[TBL] [Abstract][Full Text] [Related]
25. Bioreactor and process design for large-scale mammalian cell culture manufacturing.
Nelson KL; Geyer S
Bioprocess Technol; 1991; 13():112-43. PubMed ID: 1367130
[TBL] [Abstract][Full Text] [Related]
26. Mini-review: Equipment evaluation for process scalability and readiness for current Good Manufacturing Practices in cell therapy workflows.
Verbarendse M; Snyder R; Lakshmipathy U
Cytotherapy; 2023 Oct; 25(10):1107-1112. PubMed ID: 37294247
[TBL] [Abstract][Full Text] [Related]
27. Multivariate data analysis in cell gene therapy manufacturing.
Emerson J; Kara B; Glassey J
Biotechnol Adv; 2020 Dec; 45():107637. PubMed ID: 32980438
[TBL] [Abstract][Full Text] [Related]
28. How do I structure logistic processes in preparation for outsourcing of cellular therapy manufacturing?
Chen LN; Collins-Johnson N; Sapp N; Pickett A; West K; Stroncek DF; Panch SR
Transfusion; 2019 Aug; 59(8):2506-2518. PubMed ID: 31135995
[TBL] [Abstract][Full Text] [Related]
29. A Universal and Robust Integrated Platform for the Scalable Production of Human Cardiomyocytes From Pluripotent Stem Cells.
Fonoudi H; Ansari H; Abbasalizadeh S; Larijani MR; Kiani S; Hashemizadeh S; Zarchi AS; Bosman A; Blue GM; Pahlavan S; Perry M; Orr Y; Mayorchak Y; Vandenberg J; Talkhabi M; Winlaw DS; Harvey RP; Aghdami N; Baharvand H
Stem Cells Transl Med; 2015 Dec; 4(12):1482-94. PubMed ID: 26511653
[TBL] [Abstract][Full Text] [Related]
30. Achieving continuous manufacturing for final dosage formation: challenges and how to meet them. May 20-21, 2014 Continuous Manufacturing Symposium.
Byrn S; Futran M; Thomas H; Jayjock E; Maron N; Meyer RF; Myerson AS; Thien MP; Trout BL
J Pharm Sci; 2015 Mar; 104(3):792-802. PubMed ID: 25501530
[TBL] [Abstract][Full Text] [Related]
31. Addressing the Manufacturing Challenges of Cell-Based Therapies.
de Almeida Fuzeta M; de Matos Branco AD; Fernandes-Platzgummer A; da Silva CL; Cabral JMS
Adv Biochem Eng Biotechnol; 2020; 171():225-278. PubMed ID: 31844924
[TBL] [Abstract][Full Text] [Related]
32. Sensor technologies for quality control in engineered tissue manufacturing.
McCorry MC; Reardon KF; Black M; Williams C; Babakhanova G; Halpern JM; Sarkar S; Swami NS; Mirica KA; Boermeester S; Underhill A
Biofabrication; 2022 Oct; 15(1):. PubMed ID: 36150372
[TBL] [Abstract][Full Text] [Related]
33. Integrated viral clearance strategies-reflecting on the present, projecting to the future.
Roush DJ
Curr Opin Biotechnol; 2018 Oct; 53():137-143. PubMed ID: 29367164
[TBL] [Abstract][Full Text] [Related]
34. Automated disposable small scale reactor for high throughput bioprocess development: a proof of concept study.
Bareither R; Bargh N; Oakeshott R; Watts K; Pollard D
Biotechnol Bioeng; 2013 Dec; 110(12):3126-38. PubMed ID: 23775295
[TBL] [Abstract][Full Text] [Related]
35. The translation of cell-based therapies: clinical landscape and manufacturing challenges.
Heathman TR; Nienow AW; McCall MJ; Coopman K; Kara B; Hewitt CJ
Regen Med; 2015; 10(1):49-64. PubMed ID: 25562352
[TBL] [Abstract][Full Text] [Related]
36. Automation, Monitoring, and Standardization of Cell Product Manufacturing.
Doulgkeroglou MN; Di Nubila A; Niessing B; König N; Schmitt RH; Damen J; Szilvassy SJ; Chang W; Csontos L; Louis S; Kugelmeier P; Ronfard V; Bayon Y; Zeugolis DI
Front Bioeng Biotechnol; 2020; 8():811. PubMed ID: 32766229
[TBL] [Abstract][Full Text] [Related]
37. Throughput Optimization of Continuous Biopharmaceutical Manufacturing Facilities.
Garcia FA; Vandiver MW
PDA J Pharm Sci Technol; 2017; 71(3):189-205. PubMed ID: 27974629
[TBL] [Abstract][Full Text] [Related]
38. Manufacturing Exosomes: A Promising Therapeutic Platform.
Colao IL; Corteling R; Bracewell D; Wall I
Trends Mol Med; 2018 Mar; 24(3):242-256. PubMed ID: 29449149
[TBL] [Abstract][Full Text] [Related]
39. Biopharmaceutical Industry Approaches to Facility Segregation for Viral Safety: An Effort from the Consortium on Adventitious Agent Contamination in Biomanufacturing.
Barone PW; Avgerinos S; Ballard R; Brussel A; Clark P; Dowd C; Gerentes L; Hart I; Keumurian FJ; Kindermann J; Leung JC; Ly N; Mink S; Minning S; Mullberg J; Murphy M; Nöske K; Parriott S; Shum B; Wiebe ME; Springs SL
PDA J Pharm Sci Technol; 2019; 73(2):191-203. PubMed ID: 30361281
[TBL] [Abstract][Full Text] [Related]
40. Filling the gap: the workforce of tomorrow for CGT manufacturing as the sector advances.
Hopewell E; Pike NR; Lembong J; Hewitt M; Fekete N
Cytotherapy; 2024 Jun; 26(6):540-545. PubMed ID: 38573277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
